Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,263
  • Shares Outstanding, K 47,849
  • Annual Sales, $ 160 K
  • Annual Income, $ -14,400 K
  • 60-Month Beta -0.84
  • Price/Sales 572.43
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade AIM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8950 +4.22%
on 08/19/21
2.2000 -10.23%
on 09/02/21
+0.0250 (+1.28%)
since 08/17/21
3-Month
1.8950 +4.22%
on 08/19/21
2.2200 -11.04%
on 06/25/21
-0.1950 (-8.99%)
since 06/17/21
52-Week
1.6500 +19.70%
on 11/24/20
3.0600 -35.46%
on 02/10/21
-0.0850 (-4.13%)
since 09/17/20

Most Recent Stories

More News
TRADE X acquires automotive export specialist Techlantic

Automotive trade platform TRADE X has acquired vehicle export specialist Techlantic after raising $45 million over the summer.

AIM : 1.9800 (+0.51%)
AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company's efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of...

AIM : 1.9800 (+0.51%)
2 Biotech Stocks Focused on Fighting the Coronavirus that Could Double in Price

As the rapid spread of the COVID-19 Delta variant continues to disrupt several economies, there is growing concern about the virus’ potential long-term physical effects. Given this backdrop, which suggests...

HGEN : 6.60 (-0.90%)
AIM : 1.9800 (+0.51%)
AIM ImmunoTech Provides Second Quarter 2021 Business Update

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.

AIM : 1.9800 (+0.51%)
AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the state's life sciences industry association.

ADMA : 1.2100 (+0.83%)
SRTSU : 6.45 (-0.77%)
AIM : 1.9800 (+0.51%)
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal antiviral...

AIM : 1.9800 (+0.51%)
ORPH : 4.67 (+1.52%)
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming...

AIM : 1.9800 (+0.51%)
AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company's Phase 1 clinical study to assess the safety, tolerability and biological activity of...

AIM : 1.9800 (+0.51%)
Bluejay Mining plc Exploitation and Closure Plan Permit Received

/PRNewswire/ -- Bluejay Mining plc ("Bluejay" or the "Company") (EPIC: JAY) (Market: AIM) (Sector: Mining), the AIM, FSE listed and OTCQB traded exploration and development company with projects in and...

AIM : 1.9800 (+0.51%)
AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers...

AIM : 1.9800 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 2.0567
2nd Resistance Point 2.0233
1st Resistance Point 1.9967
Last Price 1.9800
1st Support Level 1.9367
2nd Support Level 1.9033
3rd Support Level 1.8767

See More

52-Week High 3.0600
Fibonacci 61.8% 2.5214
Fibonacci 50% 2.3550
Fibonacci 38.2% 2.1886
Last Price 1.9800
52-Week Low 1.6500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar